Germany's
largest drugmaker, Bayer AG, expects to obtain approval within two years from
China to expand the uses for its anti-clotting drug Xarelto to include stroke
prevention.
Xarelto is one of three new anti-blood
clotting pills expected to replace the decades-old and problematic stroke
preventer Warfarin. The other two are Boehringer Ingelheim's Pradaxa, and
Eliquis, developed by Bristol-Myers Squibb and Pfizer.
Xarelto has already won approvals from the
United States, European Union, Malaysia and Japan for use to prevent stroke in
patients with atrial fibrillation, or an irregular heartbeat.
Approvals from other countries are expected in
coming months, said Richard Nieman, Bayer's vice president and head of global
medical affairs in Asia.
Bayer has said it expects more than 2 billion
euros ($2.7 billion) in peak annual sales from the product, which Bayer
co-developed with Johnson & Johnson.
"For this year, we expect the bulk of
approvals...in the next year or so. We absolutely expect approval in
China," Nieman said in an interview in Singapore. Nieman said the company
expects the drug to sell well because "cardiovascular disease is on the
rise in Asia and it is under-diagnosed."
One out of every five deaths in China is now
due to stroke, with other major causes of death being cancer, respiratory and
heart-related diseases, according to China's health ministry.
Xarelto, which uses the active ingredient
rivaroxaban, is approved in more than 110 countries, including China, to fight
deep-vein thrombosis in patients undergoing hip or knee surgery.
Reuters
Business & Investment Opportunities
YourVietnamExpert is a division of Saigon Business Corporation Pte Ltd, Incorporated in Singapore since 1994. As Your Business Companion, we propose a range of services in Consulting, Investment and Management, focusing three main economic sectors: International PR; Healthcare & Wellness;and Tourism & Hospitality. We also propose Higher Education, as a bridge between educational structures and industries, by supporting international programs. Sign up with twitter to get news updates with @SaigonBusinessC. Thanks.

No comments:
Post a Comment